MedTrace Logo

Q-Switched Nd:YAG in Macular Amyloidosis

NCT00353392 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-12-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether Q-Switched Nd:YAG Laser therapy are effective in reduction of Cutaneous macular amyloidosis.

Conditions

  • Macular Amyloidosis

Interventions

DEVICE

Laser Therapy

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Principal Investigators

  • Nima Ostovari, M.D. · Shahid Beheshti University of Medical Sciences

  • Parviz Toossi, MD · Shaheed Beheshti Medica University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-07-31
Completion
2006-08-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353392 on ClinicalTrials.gov